Stoke Therapeutics, Inc. is a pioneering biopharmaceutical company based in Bedford, Massachusetts, dedicated to developing cutting-edge antisense oligonucleotide (ASO) therapies for severe genetic disorders. Leveraging its proprietary technology platform, Stoke is at the forefront of genetic medicine, committed to unraveling and treating the root causes of these complex conditions. The company boasts a promising pipeline of ASO therapies, positioning itself as an attractive investment opportunity for institutional investors interested in the transformative potential of genetic therapeutics in the biopharmaceutical landscape. Show more

Location: 45 WIGGINS AVENUE, BEDFORD, MA, UNITED STATES, 01730, Bedford, MA, 01730, USA | Website: https://www.stoketherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.733B

52 Wk Range

$5.35 - $38.69

Previous Close

$30.34

Open

$30.00

Volume

549,022

Day Range

$29.35 - $31.49

Enterprise Value

1.489B

Cash

83.39M

Avg Qtr Burn

-30.37M

Insider Ownership

4.06%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zorevunersen (STK-001) Details Dravet syndrome, Epilepsy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
STK-002 Details Autosomal Dominant Optic Atrophy (ADOA)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.